8,174 Shares in Pfizer Inc. (NYSE:PFE) Bought by Capital Performance Advisors LLP

Capital Performance Advisors LLP bought a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 8,174 shares of the biopharmaceutical company’s stock, valued at approximately $237,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Olistico Wealth LLC bought a new position in shares of Pfizer during the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer in the 2nd quarter valued at about $29,000. Quarry LP acquired a new stake in shares of Pfizer in the second quarter valued at approximately $31,000. Financial Connections Group Inc. acquired a new position in shares of Pfizer during the second quarter worth approximately $34,000. Finally, ESL Trust Services LLC bought a new stake in Pfizer during the 1st quarter valued at $37,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Down 1.7 %

Shares of Pfizer stock traded down $0.46 during trading on Friday, hitting $27.00. The stock had a trading volume of 14,240,952 shares, compared to its average volume of 37,391,438. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $31.54. The stock has a 50 day simple moving average of $28.96 and a 200 day simple moving average of $28.64. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $153.01 billion, a PE ratio of 37.11, a P/E/G ratio of 0.88 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.17) EPS. On average, research analysts expect that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.22%. Pfizer’s payout ratio is presently 227.03%.

Insider Buying and Selling at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $282,400. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of several research analyst reports. Wells Fargo & Company raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Citigroup started coverage on Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 target price on the stock. Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Sanford C. Bernstein began coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Finally, StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.